Revisiting a case of idiopathic hypereosinophilic syndrome with novel molecular techniques identifies a second case of a myeloid/lymphoid neoplasm with a SART3::PDGFRB fusion

Br J Haematol. 2023 Jul;202(1):e7-e10. doi: 10.1111/bjh.18849. Epub 2023 May 2.

Authors

Quentin Van Thillo¹, Barbara Dewaele², Jolien De Bie², Lucienne Michaux², Timothy Devos^{1

3}, Peter Vandenberghe^{1

2}

Affiliations

¹ Department of Haematology, University Hospitals Leuven, Leuven, Belgium.
² Department of Human Genetics, KU Leuven, Leuven, Belgium.
³ Department of Microbiology and Immunology, Laboratory of Molecular Immunology (Rega Institute), KU Leuven, Leuven, Belgium.

PMID: 37129059
DOI: 10.1111/bjh.18849

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antigens, Neoplasm
Humans
Hypereosinophilic Syndrome* / diagnosis
Hypereosinophilic Syndrome* / genetics
Lymphoma*
Myeloproliferative Disorders*
Oncogene Proteins, Fusion / genetics
RNA-Binding Proteins
Receptor, Platelet-Derived Growth Factor beta

Substances

Receptor, Platelet-Derived Growth Factor beta
Oncogene Proteins, Fusion
SART3 protein, human
Antigens, Neoplasm
RNA-Binding Proteins
PDGFRB protein, human